Lannett announces launch of Fluphenazine HCl Tablets

Lannett Company, Inc. (AMEX: LCI), a manufacturer of generic pharmaceuticals, today announced that it has commenced shipping Fluphenazine HCl Tablets USP, the generic equivalent of Prolixin^®, in 1 mg, 2.5 mg, 5 mg and 10 mg dosages. For the 12 months ended September 2010, Fluphenazine HCl Tablets USP, 1 mg, 2.5 mg, 5 mg, & 10 mg had U.S. sales of approximately $28 million at Average Wholesale Price. Lannett acquired an FDA approved Abbreviated New Drug Application (ANDA) for Fluphenazine HCl Tablets USP, in 1 mg, 2.5 mg, 5 mg and 10 mg dosages.

“Fluphenazine represents our second product launch resulting from an acquired ANDA. We continue to seek additional opportunities to expand our portfolio through collaboration or the purchase of complementary products.”

"To broaden our product offering and help offset the FDA backlog, we augment our internal drug development efforts with strategic alliances and product acquisitions," said Arthur Bedrosian, president and chief executive officer of Lannett. "Fluphenazine represents our second product launch resulting from an acquired ANDA. We continue to seek additional opportunities to expand our portfolio through collaboration or the purchase of complementary products."

Fluphenazine HCl Tablets USP, 1 mg, 2.5 mg, 5 mg and 10 mg are antipsychotic agents used in the treatment of schizophrenia and other mental illnesses.

SOURCE Lannett Company, Inc.